...
首页> 外文期刊>Breast Cancer Research >Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
【24h】

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

机译:可以通过免疫组织化学生物标记物鉴定出具有四个或更多受累腋窝淋巴结的乳腺癌患者的临床相关预后子集吗?组织芯片可行性研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionPrimary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups.MethodsPatients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a 'test set' and a 'validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan–Meier method, log rank tests and Cox proportional-hazards models.ResultsA total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked.ConclusionBiomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology.
机译:前言涉及四个或更多腋窝淋巴结的原发性乳腺癌预后较差。我们假设使用免疫组织化学生物标记评分系统可以识别可变风险亚组。方法从临床注释的福尔马林固定石蜡包埋的原发性乳腺癌组织芯片中鉴定出具有四个或更多腋窝淋巴结阳性的患者,并将其随机分为“测试集”和“验证集”。在测试集中建立了前瞻性定义的预后评分模型,并在验证集中通过免疫组织化学结合八个生物标志物的表达对其进行了评估,包括雌激素受体,人表皮生长因子受体1和2,碳酸酐酶IX,细胞角蛋白5/6,孕激素受体,p53和Ki-67。通过Kaplan-Meier方法,对数秩检验和Cox比例风险模型分析了生存结局。结果在测试集中共鉴定出313名合格患者,其10年无复发生存率为38.3%(SEM 2.9%) ,其中包括227个完整的免疫组化数据。肿瘤大小,阳性腋窝淋巴结百分比和孕激素受体,Ki-67和碳酸酐酶IX的表达状态证明了对无复发生存的独立预后意义。我们的组合生物标记评分系统在测试集中定义了三个亚组,其10年平均无复发生存率分别为75.4%(SEM 7.0%),35.3%(SEM 4.1%)和19.3%(SEM 7.0%)。在验证集中,这些亚组的无复发生存率差异仍具有统计学意义,但差异不显着。结论本文评估的生物标志物具有四个或更多腋窝淋巴结阳性的乳腺癌独立预后价值,并确定了临床相关的预后亚组。这种方法需要改进和验证方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号